Neuphoria Therapeutics (NEUP) Competitors $7.56 -0.14 (-1.82%) As of 07/15/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock NEUP vs. ABVC, CUE, OSTX, GANX, ATRA, RNXT, RENB, QNTM, CRVO, and AADIShould you be buying Neuphoria Therapeutics stock or one of its competitors? The main competitors of Neuphoria Therapeutics include ABVC BioPharma (ABVC), Cue Biopharma (CUE), OS Therapies (OSTX), Gain Therapeutics (GANX), Atara Biotherapeutics (ATRA), RenovoRx (RNXT), Renovaro (RENB), Quantum Biopharma (QNTM), CervoMed (CRVO), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Neuphoria Therapeutics vs. Its Competitors ABVC BioPharma Cue Biopharma OS Therapies Gain Therapeutics Atara Biotherapeutics RenovoRx Renovaro Quantum Biopharma CervoMed Aadi Bioscience Neuphoria Therapeutics (NASDAQ:NEUP) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, NEUP or ABVC? ABVC BioPharma has higher revenue and earnings than Neuphoria Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuphoria Therapeutics$10K1,421.28-$15.49MN/AN/AABVC BioPharma$508.38K119.25-$4.90M-$0.13-27.46 Which has more risk & volatility, NEUP or ABVC? Neuphoria Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Do insiders and institutionals believe in NEUP or ABVC? 15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 0.7% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 17.1% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is NEUP or ABVC more profitable? Neuphoria Therapeutics has a net margin of 0.00% compared to ABVC BioPharma's net margin of -963.46%. Neuphoria Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Neuphoria TherapeuticsN/A N/A N/A ABVC BioPharma -963.46%-29.62%-14.08% Do analysts recommend NEUP or ABVC? Neuphoria Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 177.78%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ABVC BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer NEUP or ABVC? In the previous week, ABVC BioPharma had 4 more articles in the media than Neuphoria Therapeutics. MarketBeat recorded 5 mentions for ABVC BioPharma and 1 mentions for Neuphoria Therapeutics. Neuphoria Therapeutics' average media sentiment score of 1.87 beat ABVC BioPharma's score of 0.47 indicating that Neuphoria Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neuphoria Therapeutics Very Positive ABVC BioPharma Neutral SummaryNeuphoria Therapeutics beats ABVC BioPharma on 10 of the 14 factors compared between the two stocks. Get Neuphoria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NEUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NEUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEUP vs. The Competition Export to ExcelMetricNeuphoria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.48M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.2228.5419.58Price / Sales1,421.28298.23430.1194.56Price / CashN/A43.1536.0257.93Price / Book0.487.568.145.54Net Income-$15.49M-$55.11M$3.24B$257.73M7 Day Performance1.34%3.81%0.17%-0.08%1 Month Performance12.84%11.60%5.95%8.09%1 Year PerformanceN/A-2.11%26.22%13.02% Neuphoria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEUPNeuphoria Therapeutics2.2195 of 5 stars$7.56-1.8%$21.00+177.8%N/A$14.48M$10K0.00N/AABVCABVC BioPharma0.4 of 5 stars$3.03-2.3%N/A+349.6%$52.81M$510K-23.3130News CoverageHigh Trading VolumeCUECue Biopharma4.1243 of 5 stars$0.69-0.6%$3.00+336.0%-24.7%$52.38M$9.29M-1.0360Positive NewsGap DownOSTXOS Therapies2.2177 of 5 stars$1.87-2.1%$18.00+862.6%N/A$51.42MN/A-2.17N/AAnalyst ForecastGap UpHigh Trading VolumeGANXGain Therapeutics2.353 of 5 stars$1.69+3.4%$8.20+385.2%+36.0%$50.61M$50K-1.9720News CoverageATRAAtara Biotherapeutics4.4098 of 5 stars$8.01-2.9%$17.75+121.6%-16.9%$50.46M$199.73M-2.15330News CoverageRNXTRenovoRx2.5038 of 5 stars$1.35+3.8%$7.25+437.0%+3.9%$49.74M$40K-3.386RENBRenovaro1.8867 of 5 stars$0.28-0.5%N/A-80.0%$49.73MN/A-0.3620QNTMQuantum BiopharmaN/A$17.15-10.5%N/AN/A$49.60MN/A-1.07N/ACRVOCervoMed3.2813 of 5 stars$5.72+2.9%$27.63+383.0%-59.9%$49.17M$9.74M-2.624News CoverageAADIAadi Bioscience0.3796 of 5 stars$1.99+5.9%$1.67-16.2%+37.6%$49.15M$25.07M-0.8740 Related Companies and Tools Related Companies ABVC Competitors CUE Competitors OSTX Competitors GANX Competitors ATRA Competitors RNXT Competitors RENB Competitors QNTM Competitors CRVO Competitors AADI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NEUP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
